Integrated Report 2024 PHC Group Overview and VisionAt a Glance PHC Group Overview and Vision PHC Group Business Strategy PHC Group Sustainability Data Section PHC Group History CEO Message At a Glance Value Creation Process Overview of Mid-Term Plan CxO/Domain Head Message PHC Group Products and Services Supporting Our Everyday Life Sustainability Roundtable Financial Non-Financial Financial Consolidated revenue Ratio of consolidated revenue Consolidated operating profit Cash based profit per share, dividends,dividend payout ratio FY2022 FY2023 Cash based profit attributable to owners of the parent per share*1 (yen) 180.2 84.7 Dividend per share (yen) 72 54 Dividend payout ratio*2 (%) 39.9 63.7 Cash based profit attributable to owners of the parent company = Profit attributable to owners of the parent + Impairment loss (excluding marketable securities) + M&A related income and expenses (depreciable assets) + mark-to-market gain/loss from convertible notes + tax effect for adjustment items. Per share calculation for FY21 and FY22 is based on the average number of shares outstanding during the period (net of treasury stock), and those for FY23 (forecast) are based on the number of shares outstanding at the end of the fiscal year ended March 31, 2023 (after deducting treasury stock at the end of the fiscal year). Dividend payout ratio (%) = Dividend per share/CBNI per share Non-Financial *PHCHD *Top 20 in the 50 largest revenue pharma companies in the world in 2022 *In some areas or countries, it may be called Chomolungma, Sagarmatha, or other names.